Third Pivotal Phase 3 Study For NicOx’ Naproxcinod Shows Positive Efficacy, Safety And Blood Pressure Results
NicOx S.A. (NYSE Euronext Paris: COX) announced that the third pivotal phase 3 study for naproxcinod in patients with OA of the hip showed a highly statistically significant result (p
More: continued here
Filed under: Clinical Trials on November 25th, 2008